Relationship of P-glycoprotein and p53 protein to chemosensitivity in colorectal cancer

1997 ◽  
Vol 2 (2) ◽  
pp. 81-91 ◽  
Author(s):  
Keiko Yagi ◽  
Kazufumi Kunitomo ◽  
Kunio Ii ◽  
Seiki Tashiro
Keyword(s):  
Colorectal Cancer ◽  
P53 Protein ◽  
P Glycoprotein ◽  
Relationship Of

Accumulation of p53 protein and overexpression of the HER3 receptor in colorectal cancer

2015 ◽  
Vol 73 (2) ◽  
pp. 158-164
Author(s):  
Siham Amsaguine ◽  
Sara El Mhaia ◽  
Houda Drissi ◽  
Chrifa Amer ◽  
Mohammed Ahallat ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
P53 Protein ◽  
Her3 Receptor

scholarly journals MDR1 polymorphisms are not related to Xeliri and Xelox chemoresistance in colorectal cancer

2019 ◽  
Author(s):  
Ayat B. Al-Ghafari ◽  
Areej M. Alqahtani ◽  
Suzan N. Alturki ◽  
Huda Abdulaziz Al Doghaither ◽  
Hanaa M. Tashkandi ◽  
...  
Keyword(s):  
Colorectal Cancer ◽  
Drug Response ◽  
Fragment Length Polymorphism ◽  
Protective Role ◽  
Genotype Distribution ◽  
Chain Reaction ◽  
P Glycoprotein ◽  
Significant Difference ◽  
Pcr Rflp ◽  
Polymerase Chain

Abstract Background Multidrug resistance member 1 (MDR1) is located on chromosome 7 and encodes P-glycoprotein (Pgp), which is universally accepted as a drug resistance biomarker. MDR1 polymorphisms may change either the protein expression or function, suggesting its possible association with cancers, including colorectal cancer (CRC). Thus, this study aimed to determine the effects of MDR1 polymorphisms on the drug response of Saudi CRC patients.Methods DNA samples were obtained from 62 CRC patients and 100 healthy controls. The genotypes and allele frequencies of the MDR1 polymorphisms G2677T and T1236C were determined by polymerase chain reaction–restriction fragment length polymorphism (PCR-RFLP).Results No significant difference was observed in the genotype distribution and allele frequency of T1236C between the CRC the patients and the controls. However, G2677T was found to play a highly significant protective role against the progression of CRC. Moreover, the results showed that none of the genotypes in SNPs T1236C and G2677T affected chemoresistance to Xeliri and Xelox.Conclusions T1236C in the MDR1 gene is not related to CRC risk, and G2677T protects against the development of CRC. Both MDR1 polymorphisms are not associated with the risk of chemoresistance.

Immunohistochemical Expression of p53 Protein and P-glycoprotein and its Prognostic Significance in Osteosarcoma

1999 ◽  
Vol 34 (5) ◽  
pp. 859
Author(s):  
Sang Hoon Lee ◽  
Yong Bum Park ◽  
Han Soo Kim ◽  
Chong Jai Kim ◽  
Woo Jin Kim ◽  
...  
Keyword(s):  
P53 Protein ◽  
Prognostic Significance ◽  
Immunohistochemical Expression ◽  
P Glycoprotein

scholarly journals MRN (MRE11-RAD50-NBS1) Complex in Human Cancer and Prognostic Implications in Colorectal Cancer

2019 ◽  
Vol 20 (4) ◽  
pp. 816 ◽  
Author(s):  
Yiling Situ ◽  
Liping Chung ◽  
Cheok Lee ◽  
Vincent Ho
Keyword(s):  
Colorectal Cancer ◽  
Cancer Progression ◽  
Human Cancer ◽  
Progression Free Survival ◽  
Current Evidence ◽  
Treatment Target ◽  
Free Survival ◽  
Mrn Complex ◽  
Prognostic Implications ◽  
Relationship Of

The MRE11-RAD50-NBS1 (MRN) complex has been studied in multiple cancers. The identification of MRN complex mutations in mismatch repair (MMR)-defective cancers has sparked interest in its role in colorectal cancer (CRC). To date, there is evidence indicating a relationship of MRN expression with reduced progression-free survival, although the significance of the MRN complex in the clinical setting remains controversial. In this review, we present an overview of the function of the MRN complex, its role in cancer progression, and current evidence in colorectal cancer. The evidence indicates that the MRN complex has potential utilisation as a biomarker and as a putative treatment target to improve outcomes of colorectal cancer.

Sign in / Sign up

Export Citation Format

Share Document